Romerol2 mg

Romerol is a thiazolidinedione (TZD) class oral antidiabetic agent approved for the management of type 2 diabetes mellitus in adults, used to improve glycemic control in conjunction with diet and exercise.

Established/FDA-approved uses

• Monotherapy: Romerol may be used as a single agent when diet and exercise alone do not adequately control blood glucose.
• Combination therapy: Romerol may be used together with metformin or a sulfonylurea when either agent alone, plus diet and exercise, does not achieve adequate glycemic control.

Important note on current use

Use of Romerol has declined substantially since post-marketing data raised concerns about cardiovascular safety (see Precautions and Warnings). It is no longer considered a first-line antidiabetic and, in many regulatory jurisdictions, its use is now restricted to patients who cannot achieve glycemic control with other agents and for whom the potential benefit is judged to outweigh cardiovascular risk after individualized discussion. Romerol is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis, and is not a substitute for insulin in patients who require insulin.

Each tablet contains Rosiglitazone (as Rosiglitazone maleate) as the active pharmaceutical ingredient, commonly available in strengths of 2 mg, 4 mg, and 8 mg for oral administration. Tablets also contain standard pharmaceutical excipients such as lactose, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate; exact excipients vary by manufacturer.

Romerol is an oral antihyperglycemic agent belonging to the thiazolidinedione (glitazone) class, used in the management of type 2 diabetes mellitus. It works by improving the sensitivity of muscle, fat, and liver tissue to endogenous and exogenous insulin, thereby lowering blood glucose without directly stimulating insulin secretion.

Romerol was widely prescribed after its introduction, but its use has substantially declined following post-marketing safety signals for cardiovascular ischemic events and worsening heart failure. It remains available in some markets under specific restrictions, and is generally reserved as a second-line or adjunct option after a careful risk-benefit assessment.

Romerol belongs to the thiazolidinedione (TZD) class of oral antidiabetic/insulin-sensitizing agents, also referred to as glitazones or PPAR-gamma agonists.

Rosiglitazone is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor found in adipose tissue, skeletal muscle, and liver. Activation of PPAR-γ modulates the transcription of insulin-responsive genes involved in glucose production, transport, and utilization.

By increasing peripheral insulin sensitivity, Rosiglitazone lowers blood glucose without increasing pancreatic insulin secretion, distinguishing it mechanistically from sulfonylureas. Effects on glycemic control typically develop gradually over several weeks, with maximal effect seen after 8-12 weeks of therapy. Rosiglitazone is extensively metabolized by the liver (primarily via CYP2C8, with a minor contribution from CYP2C9) and has a plasma half-life of approximately 3-4 hours, though its pharmacodynamic effect is more prolonged.

Romerol tablets are for oral use only. They can be administered without regard to meals. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped-doses should not be doubled.

The following are well-established, clinically significant interactions with Romerol:

• Gemfibrozil: A CYP2C8 inhibitor that can substantially increase Romerol plasma concentrations; a lower dose of Romerol may be required if co-administered, with close glucose monitoring.
• Rifampicin (rifampin) and other CYP2C8 inducers: May significantly reduce Romerol plasma levels and reduce its glycemic effect; dose adjustment of Romerol may be needed.
• Insulin: Concomitant use is generally not recommended due to an increased risk of fluid retention, edema, and heart failure; if combined, low-dose initiation and close monitoring for signs of heart failure are required.
• Other oral antidiabetic agents (sulfonylureas, metformin): Combination increases risk of hypoglycemia (particularly with sulfonylureas) and additive fluid-retention risk; dose adjustment and monitoring are recommended.
• Oral contraceptives: Romerol may modestly reduce plasma concentrations of ethinyl estradiol and norethindrone; alternative or additional contraceptive methods should be considered.

Adverse effects reported with Romerol include:

Common

• Upper respiratory tract infection, headache
• Weight gain
• Mild-to-moderate peripheral edema (fluid retention)
• Anemia (usually dilutional, from increased plasma volume)
• Increases in total and LDL cholesterol

Serious (less common but clinically important)

• New-onset or worsening congestive heart failure (see Contraindications and Precautions)
• Increased risk of myocardial ischemic events reported in post-marketing meta-analyses, contributing to restricted use of Romerol (see Precautions and Warnings)
• Increased incidence of bone fractures, particularly in women, typically involving the distal upper limb and foot
• Hepatotoxicity (rare; periodic liver function monitoring is advised)
• Macular edema (rare)

Pregnancy: Data on the use of Romerol during human pregnancy are limited. As glycemic control is generally better achieved with insulin during pregnancy, Romerol is not recommended for use in pregnant women; if used, it should be given only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under close physician supervision. Women of childbearing potential should discuss contraception and pregnancy planning with their physician before starting Romerol, given the also-reduced effectiveness of oral contraceptives noted under Interactions.

Lactation: It is not known whether Romerol is excreted in human breast milk; because many drugs are excreted in breast milk and the potential for adverse effects on the nursing infant is unknown, a decision should be made to discontinue nursing or discontinue Romerol, taking into account the importance of the drug to the mother, in consultation with a physician.

Heart failure and fluid retention

Romerol can cause fluid retention, which may lead to or worsen congestive heart failure; it is contraindicated in NYHA Class III/IV heart failure (see Contraindications) and should be used with caution in patients with existing edema, milder heart failure (NYHA Class I/II), or risk factors for heart failure. Patients should be monitored for signs and symptoms of heart failure (rapid weight gain, dyspnea, edema); if these develop, Romerol should be discontinued or its dose reduced.

Cardiovascular ischemic risk and restricted use

Post-marketing meta-analyses raised concern for an increased risk of myocardial ischemic events (such as angina or myocardial infarction) associated with Romerol. This evolved safety signal led several regulatory authorities to restrict prescribing, require special access programs, or withdraw Romerol from the market entirely in some jurisdictions. As a result, Romerol is no longer considered a first-line or routine antidiabetic choice; it should be reserved for patients in whom other treatment options are unsuitable or ineffective, following an individualized discussion of cardiovascular risks and benefits, and is not recommended in patients with known ischemic heart disease unless no other suitable option exists.

Hepatic effects

Because earlier agents in the thiazolidinedione class were associated with hepatotoxicity, baseline and periodic liver function testing is a reasonable precaution with Romerol, even though clinically significant hepatotoxicity with Romerol itself is rare. Romerol should not be started in patients with active liver disease or notably elevated baseline transaminases (see Contraindications), and should be discontinued if liver injury is suspected.

Bone fracture risk

An increased incidence of bone fractures has been observed with Romerol, more commonly in women, usually affecting the upper limb, hand, or lower leg/foot. Bone health should be considered, particularly in postmenopausal women on long-term therapy.

Macular edema

Macular edema has been reported rarely in patients taking Romerol, sometimes with concurrent peripheral edema. Patients reporting blurred vision should be referred for ophthalmologic evaluation.

Ovulation

Romerol may result in resumption of ovulation in premenopausal anovulatory women with insulin resistance, increasing the risk of unintended pregnancy; adequate contraception should be discussed (see Pregnancy and Lactation).

Limited data exist on Romerol overdose. In case of a suspected overdose, seek immediate medical attention or contact a poison control center. General supportive measures should be provided as clinically indicated based on the patient's signs and symptoms; there is no specific antidote for Romerol overdose. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment

Romerol should not be initiated in patients with active liver disease or clinically significant elevation of baseline liver enzymes (see Contraindications). Periodic monitoring of liver function is advised during therapy.

Renal impairment

No dosage adjustment of Romerol is generally required in mild-to-moderate renal impairment. Romerol has not been studied extensively in severe renal impairment or dialysis, and should be used with caution in these patients, with attention to fluid-retention risk.

Elderly

No specific dose adjustment is required based on age alone, but elderly patients may be at greater risk of heart failure and fracture-related complications; use with caution and monitor closely.

Pediatric use

See Pediatric Uses.

Romerol is intended for long-term, ongoing use as part of chronic type 2 diabetes management, with periodic reassessment of glycemic control (e.g., via HbA1c) approximately every 3 months, and ongoing monitoring for cardiovascular, hepatic, and fracture-related risks. The need for continued therapy with Romerol should be reviewed regularly by the treating physician, particularly given its restricted-use status.

Rosiglitazone is classified as a thiazolidinedione (TZD), also known as a glitazone or PPAR-gamma agonist, within the broader category of oral antidiabetic/antihyperglycemic agents.

Rosiglitazone acts as a selective agonist at the peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in adipose tissue, skeletal muscle, and liver, which reduces blood glucose without directly increasing insulin secretion from the pancreas.

C

The safety and efficacy of Romerol in pediatric patients (under 18 years of age) have not been established. Romerol is therefore not recommended for use in children and adolescents with type 2 diabetes; alternative, better-studied agents (such as metformin or insulin, per pediatric guidelines) should be used in this population.